- Page 1 and 2: WHO/HTM/TB/2004.329TB HIVA CLINICAL
- Page 3 and 4: WHO Library Cataloguing-in-Publicat
- Page 5 and 6: 2.2.4 Key operations for DOTS imple
- Page 7 and 8: 9.4 TB treatment regimens: question
- Page 9 and 10: 12.7 Neurological problems in adult
- Page 14 and 15: PREFACE TO SECOND EDITIONRecognitio
- Page 16 and 17: GLOSSARY AND ABBREVIATIONSThis glos
- Page 18 and 19: HIV-negativeHIV-positiveHIV-related
- Page 20: RNARTISCCscrofulasensitivity testse
- Page 24 and 25: BACKGROUND INFORMATION ONTUBERCULOS
- Page 26 and 27: dead, 25% will be healthy (self-cur
- Page 28 and 29: smear; upper lobe involvement; usua
- Page 30 and 31: About one-third of children born to
- Page 32 and 33: important cells in the cell-mediate
- Page 34 and 35: AdultsWHO clinical staging system f
- Page 36 and 37: 1.2.8 Epidemiological surveillance
- Page 38 and 39: 1.3.2 HIV infection and risk of TBH
- Page 40 and 41: HIV-related TB in childrenAs in adu
- Page 42 and 43: AN EXPANDED FRAMEWORK FOR EFFECTIVE
- Page 44 and 45: 2.2.3 TB control policy package (th
- Page 46 and 47: º Undertake economic analysis and
- Page 48 and 49: 2.5 DOTS-PLUSHigh levels of multidr
- Page 50 and 51: DIAGNOSIS OF PULMONARY TUBERCULOSIS
- Page 52 and 53: 3.3 DIAGNOSTIC SPUTUM SMEAR MICROSC
- Page 54 and 55: Sensitivity of sputum smear microsc
- Page 56 and 57: PRACTICAL POINTIf the patient is br
- Page 58 and 59: cavitationunilateral infiltrationbi
- Page 60 and 61: Clinical and CXR features of PCP an
- Page 62 and 63:
DIAGNOSIS OF PULMONARY TUBERCULOSIS
- Page 64 and 65:
disease to other parts of the body,
- Page 66 and 67:
(3) Respiratory symptoms such as co
- Page 68 and 69:
º evidence of wasting (i.e. under
- Page 70 and 71:
In the past, some doctors have advo
- Page 72 and 73:
productive of copious purulent and
- Page 74 and 75:
distinguishing TB-infected from non
- Page 76 and 77:
DIAGNOSIS OF EXTRAPULMONARYTUBERCUL
- Page 78 and 79:
Practical approach to investigation
- Page 80 and 81:
Clinical differentiation of miliary
- Page 82 and 83:
malignancy, post-pneumonic effusion
- Page 84 and 85:
Therapeutic pericardiocentesis is n
- Page 86 and 87:
Clinical featuresThe patient may pr
- Page 88 and 89:
5.6 OTHER FORMS OF EXTRAPULMONARY T
- Page 90:
SUGGESTIONS FOR FURTHER READINGCrof
- Page 93 and 94:
PRACTICAL POINTFull blood count (FB
- Page 95 and 96:
countries for staging and monitorin
- Page 97 and 98:
provides support. Counselling is a
- Page 99 and 100:
SUGGESTIONS FOR FURTHER READINGUNAI
- Page 101 and 102:
Lesscommonextensive fungal skin, na
- Page 103 and 104:
positive. These include the poor ou
- Page 106 and 107:
STANDARDIZED TUBERCULOSIS CASEDEFIN
- Page 108 and 109:
Pulmonary TB - sputum smear-negativ
- Page 110:
The table below shows the severe an
- Page 113 and 114:
First-line Mode of Potency Recommen
- Page 115 and 116:
growing bacilli and the killing of
- Page 117 and 118:
Recommended treatment regimens for
- Page 119 and 120:
9.4 TB TREATMENT REGIMENS: QUESTION
- Page 121 and 122:
9.5 USE OF ANTI-TB DRUGS IN SPECIAL
- Page 123 and 124:
PRACTICAL POINTRecording treatment
- Page 125 and 126:
indicators are treatment completion
- Page 127 and 128:
SCCAmong TB patients who complete S
- Page 130 and 131:
SIDE-EFFECTS OF ANTI-TUBERCULOSIS D
- Page 132 and 133:
PRACTICAL POINTRifampicin reduces t
- Page 134 and 135:
10.7.1 Treatment regimen includes t
- Page 136 and 137:
not a severe reaction) to isoniazid
- Page 138 and 139:
ANTIRETROVIRAL THERAPY FOR THETREAT
- Page 140 and 141:
eplication and functioning of HIV.
- Page 142 and 143:
18 HIV antibody º WHO Paediatric S
- Page 144 and 145:
Name of drug Formulations Pharmacok
- Page 146 and 147:
Stavudine Maximum dose: Needs to be
- Page 148 and 149:
Efavirenz 25 to 33 kg: 350 mg(EFZ)
- Page 150 and 151:
11.7 CHOICE OF ART REGIMENWHO recom
- Page 152 and 153:
Recommended first-line ARV combinat
- Page 154 and 155:
11.10 INTERACTIONS BETWEEN ARV DRUG
- Page 156:
SUGGESTIONS FOR FURTHER READINGBart
- Page 159 and 160:
worldwide. There has also been rece
- Page 161 and 162:
chlamydia doxycycline 100 mg orally
- Page 163 and 164:
º Fungal infectionsInfection Local
- Page 165 and 166:
Ichthyosis(dry scalyskin)PsoriasisE
- Page 167 and 168:
sputuminductionusing 3-5%hypertonic
- Page 169 and 170:
Where available, barium swallow sho
- Page 171 and 172:
Isospora bellitrimethoprim 80 mg/su
- Page 173 and 174:
Always check a blood film for malar
- Page 175 and 176:
It is unlikely, but possible, that
- Page 177 and 178:
a variety of neurological problems
- Page 179 and 180:
section 12.4 on skin problems), a b
- Page 181 and 182:
ChildrenIn children with known or s
- Page 183 and 184:
PathogenPneumocystis cariniiDrug re
- Page 186 and 187:
COORDINATED CARE IN DIFFERENT SETTI
- Page 188 and 189:
º access to voluntary counselling
- Page 190 and 191:
13.5.3 Secondary careMeasures appli
- Page 192 and 193:
Secondary care As for primary As pe
- Page 194:
SUGGESTIONS FOR FURTHER READINGGilk
- Page 197 and 198:
PRACTICAL POINTIn wards, outpatient
- Page 199 and 200:
14.3.2 BCG protection against TB in
- Page 201 and 202:
) Aimed at decreasing risk of a rec
- Page 203 and 204:
to exclude active TB and to ensure
- Page 205 and 206:
SUGGESTIONS FOR FURTHER READINGHarr
- Page 207 and 208:
Childrenapproach to TB diagnosis .
- Page 209 and 210:
Kaposi sarcoma . . . . . . . . . .3
- Page 211 and 212:
Target groups for preventive treatm